HIV-1 subtype as a determinant of disease progression

Journal of Infectious Diseases

Volumn 197, Issue 5, 2008, Pages 638-639

  Kuritzkes, Daniel R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE DISTRIBUTION; DISEASE COURSE; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; NATURAL KILLER CELL; PATHOGENESIS; PRIORITY JOURNAL; SOCIOECONOMICS;

DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; UGANDA; VIRULENCE;

EID: 40549113345     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/527417     Document Type: Editorial

References (14)

1. Kuritzkes DR, Walker BD. HIV-1 pathogenesis and clinical manifestations. In: Knipe DM, Hawley PM, eds. Fields virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2007:2187-214.
2. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179:68-73.
3. Kaleebu P, French N, Mahe C, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002; 185:1244-50.
4. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 Subtype D Infection Is Associated with Faster Disease Progression than Subtype A in Spite of Similar Plasma HIV-1 Loads. J Infect Dis 2007; 195:1177-80.
5. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008; 197:707-13 (in this issue).
6. Ioannidis JPA, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-ë32, CCR2-64I, and SDF-13'A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001; 135:782-95.
7. Kaleebu P, Nankya IL, Yirrell DL, et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007; 45:28-33.
8. Laeyendecker O, Li X, Arroyo MA, et al. The effect of HIV subtype on rapid disease progression in Rakai [abstract 44LB]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver, CO). 2006.
9. Daar ES, Kesler KL, Petropoulos CJ, et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007; 45:643-9.
10. Goetz MB, Leduc R, Kostman JR, et al. Prediction of disease progression by HIV coreceptor tropism (CRT) in persons (P) with untreated chronic HIV infection [abstract H-1027]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). 2007.
11. Dolan MJ, Kulkarni H, Camargo JF, et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV/AIDS pathogenesis via viral entry-dependent and independent mechanisms. Nat Immunol 2007; 8:1324-36.
12. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535-51.
13. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733-40.
14. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27:406-16.